Editorial companion

What stands out

Novartis plunged after a third clinical-trial setback for a rare muscle-wasting disease, sliding as much as 10% in Zurich and cutting its year-to-date gain to about 4% versus Roche. Sandoz, its generics and biosimilars arm, quietly nudged up mid-term guidance and laid out an audacious plan to grow biosimilars from 13 today to more than 100 by 2040. Computacenter rallied to a record high after again raising profit-before-tax guidance for fiscal year 2026, citing a US revenue beat driven by artificial intelligence (AI) related spend. The episode neatly bundles a biotech binary shock, a long-horizon strategic pivot, and an AI-driven services upgrade into one market day.